PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Amir A. Jazaeri, Hao Nie et al.|Nature|2025Cited by 30
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancerEmily Hinchcliff, Amir A. Jazaeri, Anne Knisely et al.|Cancer|2023Cited by 18
Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer (NCT03026062)Emily Hinchcliff, Amir A. Jazaeri, Ami Patel et al.|Gynecologic Oncology|2021Cited by 8
Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099)Emily Hinchcliff, Amir A. Jazaeri, Ami Patel et al.|Gynecologic Oncology|2022Cited by 6
Immuno-oncology for Gynecologic MalignanciesJeffrey How, Amir A. Jazaeri, Ami Patel|Advances in experimental medicine and biology|2020Cited by 5